An ADP-ribose polymerase (PARP) inhibitor has received accelerated approval from the US Food and Drug Administration (FDA) for treatment of women with heavily pretreated ovarian cancer associated with defective BRCA genes.
An ADP-ribose polymerase (PARP) inhibitor has received accelerated approval from the US Food and Drug Administration (FDA) for treatment of women with heavily pretreated ovarian cancer associated with defective BRCA genes. The action on Lynparza (olaparib) was in conjunction with approval of BRACAnalysis CDx, a companion diagnostic for detection of BRCA mutations (gBRCAm) in patients with ovarian cancer.
Lynparza’s efficacy was studied in 137 women with gBRCAm-associated ovarian cancer, based on measurement of objective response rate (ORR). The results indicated that 34% of the women experienced ORR for an average of 7.9 months.
Common side effects included indigestion, fatigue, decreased appetite, back pain, rash, and cough. Serious side effects were noted including acute myeloid leukemia, lung inflammation, and myelodysplastic syndrome.
The BRACAnalysis CDx test was reviewed under the FDA’s priority review program for devices. It had previously been marketed by the manufacturer as a laboratory-developed test for use in a single laboratory. Blood samples from participants in the study of Lynparza were used to validate detection of BRCA mutations in that population.
Of the approval, Richard Pazdur, director of the Office of Hematology and Oncology Products in the Center for Drug Evaluation and Research said, “Today’s approval constitutes the first of a new class of drugs for treating ovarian cancer. Lynparza is approved for patients with specific abnormalities in the BRCA gene and is an example of how a greater understanding of the underlying mechanisms of disease can lead to targeted, more personalized treatment.”
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary OB/GYN Special Delivery.
Understanding VTE and bleeding risks in gynecologic noncancer surgery
April 15th 2024Delve into the nuanced risks of venous thromboembolism and major bleeding post-gynecologic noncancer surgery, exploring procedure-specific variations and the implications for thromboprophylaxis strategies.
Read More
Maternal history linked to uterine fibroid risk in Black women
April 11th 2024Delve into the findings of a recent study revealing the heightened risk of developing uterine fibroids among Black women with a maternal history of the condition, shedding light on crucial implications for patient care and advocacy.
Read More
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More